Mixed Cell Type Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MXD023 MIFTS: 48	Mixed Cell Type Cancer Categories: Cancer diseases, Endocrine diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Mixed Cell Type Cancer

MalaCards integrated aliases for Mixed Cell Type Cancer:

Name: Mixed Cell Type Cancer ¹¹ ¹⁴ ¹⁶

Malignant Mixed Neoplasm ¹¹ ¹⁶

Mixed Tumor, Malignant ¹¹ ⁴³

Malignant Mixed Tumor ¹¹ ⁷¹

Mixed Neoplasm ¹¹ ⁷¹

Malignant Mixed Tumor, Not Otherwise Specified ⁷¹

Mixed Tumor, Not Otherwise Specified ⁷¹

Mixed Salivary Gland Tumor ⁷¹

Malignant Mixed Cancer ¹¹

Mixed Tumor ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:154

MeSH ⁴³ D018198

NCIt ⁴⁹ C3729 C6930

SNOMED-CT ⁶⁸ 8145008

EFO ¹⁶ EFO_0007373 EFO_1000356

UMLS ⁷¹ C0026277 C0206625 C1368354 more

Sources

Summaries for Mixed Cell Type Cancer

Disease Ontology: ¹¹ A cell type cancer that has material basis in abnormally proliferating cells derives from two germinal layers of tissue.

MalaCards based summary: Mixed Cell Type Cancer, also known as malignant mixed neoplasm, is related to uterine corpus adenosarcoma and adenomyoma. An important gene associated with Mixed Cell Type Cancer is MIR542 (MicroRNA 542), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Gemcitabine and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, uterus and lymph node, and related phenotypes are Decreased viability and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Mixed Cell Type Cancer

Diseases related to Mixed Cell Type Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 794)

#	Related Disease	Score	Top Affiliating Genes
1	uterine corpus adenosarcoma	32.1	PGR MME ESR1
2	adenomyoma	31.9	PGR MME KRT7 ESR1
3	uterine body mixed cancer	31.7	TP53 PTEN PPP2R1A POLE PIK3CA KRAS
4	ovarian carcinosarcoma	31.7	TP53 PPP2R1A PIK3CA PAX8 KRAS HRAS
5	carcinosarcoma	31.1	TP53 SYP PTEN PPP2R1A PIK3CA PGR
6	adenoma	31.0	TP53 SYP PIK3CA KRT7 KRAS HRAS
7	skin benign neoplasm	30.8	TP53 SERPINA3 KRT7 KRT5 HRAS
8	malignant fibrous histiocytoma	30.5	TP53 SERPINA3 KIT
9	leiomyosarcoma	30.5	TP53 SERPINA3 PGR KIT ESR1
10	sarcoma	30.4	TP53 SERPINA3 PIK3CA KRAS KIT HRAS
11	lung benign neoplasm	30.4	TP53 SYP KRT7 KRAS HRAS
12	gallbladder cancer	30.4	TP53 PTEN PIK3CA KRT7 KRAS HRAS
13	transitional cell carcinoma	30.4	TP53 PTEN KRT7 ERBB2
14	hidradenoma	30.3	MME KRT7 KRT5
15	ameloblastoma	30.3	TP53 SERPINA3 KRAS
16	pleomorphic rhabdomyosarcoma	30.3	TP53 SERPINA3 PIK3CA HRAS
17	mediastinal cancer	30.3	SYP KRT7 KIT
18	epithelial-myoepithelial carcinoma	30.3	KRT7 KRT5 KIT
19	appendix adenocarcinoma	30.3	TP53 SYP KRT7 KRAS HRAS
20	fibroma	30.3	SERPINA3 PGR KRT7 ESR1
21	lipomatosis, multiple	30.3	TP53 SERPINA3 PTEN PIK3CA KIT
22	mesenchymal cell neoplasm	30.3	TP53 SERPINA3 MME KIT
23	thymoma	30.2	TP53 SYP KRT7 KIT HRAS
24	connective tissue benign neoplasm	30.2	TP53 SERPINA3 MME KIT H2AC18
25	papillary cystadenocarcinoma	30.2	TP53 SERPINA3 KRT7
26	ceruminoma	30.2	KRT7 KRT5
27	salivary gland adenoid cystic carcinoma	30.2	TP53 SERPINA3 KRT7 KRT5 KIT
28	adenofibroma	30.2	TP53 PAX8 MME KRT7 KRAS ARID1A
29	fallopian tube carcinoma	30.1	TP53 PTEN PAX8 KRT7 ERBB2
30	exanthem	30.1	KRAS KIT HRAS H2AC18 ERBB2
31	neurofibromatosis	30.1	TP53 PTEN KRAS KIT HRAS
32	necrotizing sialometaplasia	30.1	TP53 KRT7 KRT5
33	basaloid squamous cell carcinoma	30.1	TP53 SYP KRT7 KRT5 KIT
34	obstructive jaundice	30.1	SYP SERPINA3 KRT7
35	pheochromocytoma	30.1	SYP MME KRT7 KIT HRAS ESR1
36	bladder cancer	30.1	TP53 PTEN PIK3CA KRT7 KRAS HRAS
37	krukenberg carcinoma	30.1	SYP PAX8 KRT7
38	well-differentiated liposarcoma	30.1	TP53 SERPINA3 KIT
39	lymphoma, non-hodgkin, familial	30.1	TP53 SERPINA3 PIK3CA MME H2AC18
40	sertoli-leydig cell tumor	30.1	SYP PGR KRT7
41	vaginal discharge	30.1	PGR KRT7 ESR1
42	collecting duct carcinoma	30.1	PAX8 MME KRT7
43	adenosquamous carcinoma	30.1	SERPINA3 PGR KRT7 KRT5 KRAS HRAS
44	chordoma	30.0	TP53 SERPINA3 PTEN KRT7
45	syringocystadenoma papilliferum	30.0	SERPINA3 KRT7 KRT5 HRAS
46	spindle cell sarcoma	30.0	TP53 SERPINA3 KRT7 KIT
47	ovarian serous carcinoma	30.0	TP53 PAX8 HRAS H2AC18
48	cystic teratoma	30.0	TP53 SYP PAX8 KRT7
49	papillary adenofibroma	30.0	PTEN POLE PAX8 ARID1A
50	squamous cell carcinoma	30.0	TP53 PTEN PIK3CA KRT7 KRAS HRAS

Graphical network of the top 20 diseases related to Mixed Cell Type Cancer:

Sources

Symptoms & Phenotypes for Mixed Cell Type Cancer

GenomeRNAi Phenotypes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 42)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.37	HRAS KRAS PIK3CA
2	Decreased viability	GR00055-A-2	10.37	HRAS KRAS PIK3CA
3	Decreased viability	GR00055-A-3	10.37	KRAS
4	Decreased viability	GR00106-A-0	10.37	KRAS
5	Decreased viability	GR00221-A-1	10.37	ESR1 HRAS KIT KRAS PIK3CA
6	Decreased viability	GR00221-A-2	10.37	ESR1 HRAS KRAS PIK3CA
7	Decreased viability	GR00221-A-3	10.37	HRAS
8	Decreased viability	GR00221-A-4	10.37	ESR1 PIK3CA
9	Decreased viability	GR00301-A	10.37	KIT KRAS
10	Decreased viability	GR00381-A-1	10.37	KRAS
11	Decreased viability	GR00386-A-1	10.37	ESR1
12	Decreased viability	GR00402-S-2	10.37	ESR1 PIK3CA
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-1	10.25	POLE
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	10.25	KRAS
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-123	10.25	POLE
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	10.25	PTEN
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.25	PTEN
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	10.25	ERBB2
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	10.25	ARID1A ERBB2 POLE PTEN
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	10.25	ARID1A
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-186	10.25	ARID1A
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.25	ARID1A
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	10.25	POLE
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-207	10.25	ERBB2 POLE
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-213	10.25	ARID1A
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	10.25	PTEN
27	Increased shRNA abundance (Z-score > 2)	GR00366-A-22	10.25	KRAS
28	Increased shRNA abundance (Z-score > 2)	GR00366-A-32	10.25	ERBB2 POLE
29	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.25	PTEN
30	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.25	ARID1A
31	Increased shRNA abundance (Z-score > 2)	GR00366-A-60	10.25	ERBB2
32	Increased shRNA abundance (Z-score > 2)	GR00366-A-63	10.25	ERBB2 KRAS POLE PTEN
33	Increased shRNA abundance (Z-score > 2)	GR00366-A-66	10.25	PTEN
34	Increased shRNA abundance (Z-score > 2)	GR00366-A-73	10.25	ARID1A
35	Increased shRNA abundance (Z-score > 2)	GR00366-A-82	10.25	H2AC18
36	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.25	ERBB2 POLE
37	Increased shRNA abundance (Z-score > 2)	GR00366-A-87	10.25	ERBB2 POLE PTEN
38	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	10.25	POLE
39	Increased shRNA abundance (Z-score > 2)	GR00366-A-93	10.25	PTEN
40	Increased shRNA abundance (Z-score > 2)	GR00366-A-99	10.25	H2AC18
41	Decreased viability in pancreas lineage	GR00235-A	9.46	ARID1A KRT7 PGR TP53
42	Reduced mammosphere formation	GR00396-S	9.17	HRAS KRAS KRT7 PAX8 POLE PPP2R1A

MGI Mouse Phenotypes related to Mixed Cell Type Cancer:

⁴⁵ (show all 18)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.39	ARID1A ERBB2 ESR1 HRAS KIT KRAS
2	neoplasm	MP:0002006	10.35	ARID1A ERBB2 ESR1 HRAS KIT KRAS
3	normal	MP:0002873	10.35	ARID1A ERBB2 ESR1 HRAS KIT KRAS
4	nervous system	MP:0003631	10.33	ARID1A ERBB2 ESR1 HRAS KIT KRAS
5	muscle	MP:0005369	10.24	ARID1A ERBB2 ESR1 HRAS KIT KRAS
6	endocrine/exocrine gland	MP:0005379	10.24	ARID1A ERBB2 ESR1 HRAS KIT KRAS
7	no phenotypic analysis	MP:0003012	10.21	ARID1A ESR1 HRAS KIT KRAS PAX8
8	behavior/neurological	MP:0005386	10.2	ERBB2 ESR1 HRAS KIT KRAS KRT5
9	limbs/digits/tail	MP:0005371	10.18	ERBB2 ESR1 KIT KRAS KRT5 PAX8
10	embryo	MP:0005380	10.18	ARID1A ERBB2 ESR1 KIT KRAS PAX8
11	cellular	MP:0005384	10.18	ARID1A ERBB2 ESR1 KIT KRAS KRT7
12	digestive/alimentary	MP:0005381	10.11	ERBB2 ESR1 HRAS KIT KRAS KRT5
13	cardiovascular system	MP:0005385	10.11	ARID1A ERBB2 ESR1 HRAS KIT KRAS
14	craniofacial	MP:0005382	10.03	ARID1A ERBB2 HRAS KIT KRAS KRT5
15	immune system	MP:0005387	10.03	ARID1A ESR1 KIT KRAS KRT5 MME
16	skeleton	MP:0005390	9.9	ARID1A ERBB2 ESR1 HRAS KIT KRAS
17	mortality/aging	MP:0010768	9.8	ARID1A ERBB2 ESR1 HRAS KIT KRAS
18	integument	MP:0010771	9.44	ERBB2 ESR1 HRAS KIT KRAS KRT5

Sources

Drugs & Therapeutics for Mixed Cell Type Cancer

Drugs for Mixed Cell Type Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Gemcitabine

Approved

Phase 2, Phase 3

95058-81-4, 122111-03-9

60750

Doxorubicin

Approved, Investigational

Phase 2, Phase 3

23214-92-8

31703

Topotecan

Approved, Investigational

Phase 2, Phase 3

123948-87-8, 119413-54-6

60699 60700

Niraparib

Approved, Investigational

Phase 2, Phase 3

1038915-60-4

24958200

Pertuzumab

Approved

Phase 2, Phase 3

380610-27-5

Trastuzumab

Approved, Investigational

Phase 2, Phase 3

180288-69-1

Ifosfamide

Approved

Phase 3

3778-73-2

3690

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Mechlorethamine

Approved, Investigational

Phase 3

51-75-2

4033

Palifosfamide

Investigational

Phase 3

31645-39-3

100427

Antineoplastic Agents, Immunological

Phase 2, Phase 3

Liposomal doxorubicin

Phase 2, Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Erlotinib

Approved, Investigational

Phase 2

183319-69-9, 183321-74-6

176870

Aflibercept

Approved

Phase 2

862111-32-8

124490314

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Sorafenib

Approved, Investigational

Phase 2

284461-73-0

216239

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Lenvatinib

Approved, Investigational

Phase 2

417716-92-8

9823820

Fulvestrant

Approved, Investigational

Phase 1, Phase 2

129453-61-8

17756771 104741

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Durvalumab

Approved, Investigational

Phase 2

1428935-60-7

Tremelimumab

Approved, Investigational

Phase 2

745013-59-6

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Rucaparib

Approved, Investigational

Phase 2

283173-50-2

9931954

Olaparib

Approved

Phase 2

763113-22-0

23725625

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Doxycycline

Approved, Investigational, Vet_approved

Phase 2

564-25-0

54671203

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Cisplatin

Approved

Phase 2

15663-27-1

2767 5702198 441203

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Vorinostat

Approved, Investigational

Phase 2

149647-78-9

5311

Iniparib

Investigational

Phase 2

160003-66-7

9796068

Rivoceranib

Investigational

Phase 2

811803-05-1

11315474

MK-1775

Investigational

Phase 2

955365-80-7

24856436

Linrodostat

Investigational

Phase 2

1923833-60-6

121328278

Cediranib

Investigational

Phase 2

288383-20-0

9933475

Liver Extracts

Phase 2

Imatinib Mesylate

Phase 2

220127-57-1

Epothilones

Phase 2

Epothilone B

Phase 2

4456137

Antiviral Agents

Phase 2

Interventional clinical trials:

(show top 50) (show all 69)

#	Name	Status	NCT ID	Phase	Drugs
1	A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy	Recruiting	NCT03651206	Phase 2, Phase 3	Niraparib;Chemotherapy Drugs
2	A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma	Recruiting	NCT05256225	Phase 2, Phase 3	Carboplatin;Hyaluronidase-zzxf/Pertuzumab/Trastuzumab;Paclitaxel;Trastuzumab/Hyaluronidase-oysk
3	A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary	Active, not recruiting	NCT00954174	Phase 3	Carboplatin;Ifosfamide;Paclitaxel
4	A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus	Completed	NCT00502203	Phase 2	Carboplatin;Paclitaxel
5	Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)	Completed	NCT02993705	Phase 2	Trabectedin
6	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
7	A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus	Completed	NCT00476086	Phase 2	Gemcitabine;Oxaliplatin
8	Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors	Completed	NCT00815945	Phase 2	PegLiposomal Doxorubicin;Carboplatin
9	A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors	Completed	NCT00520013	Phase 2	bevacizumab;erlotinib;paclitaxel;carboplatin
10	Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer	Completed	NCT00511992	Phase 2	Avastin;Paclitaxel;Cisplatin
11	A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma	Completed	NCT00687687	Phase 2	paclitaxel;carboplatin;BSI-201 (Iniparib)
12	A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas	Completed	NCT00390234	Phase 2	ziv-aflibercept
13	A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00025506	Phase 2	Thalidomide
14	A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma	Completed	NCT00238121	Phase 2	sorafenib tosylate
15	A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors	Completed	NCT00231842	Phase 2	Ifosfamide;Cisplatin
16	A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer	Completed	NCT01010126	Phase 2	Temsirolimus
17	A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00114218	Phase 2	Gemcitabine Hydrochloride;Docetaxel
18	A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT00075400	Phase 2	imatinib mesylate
19	A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma	Completed	NCT03395080	Phase 2	Paclitaxel;300mg DKN-01;600mg DKN-01
20	A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01247571	Phase 2	Pazopanib Hydrochloride
21	A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus	Completed	NCT01168232	Phase 2	Ixabepilone
22	A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma	Recruiting	NCT03458728	Phase 1, Phase 2	BAY806946
23	A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers	Recruiting	NCT05156268	Phase 2	Pembrolizumab;Olaparib
24	A Phase II Trial of Pembrolizumab Plus Lenvatinib for the Treatment of Patients With Advanced Uterine and Ovarian Carcinosarcomas	Recruiting	NCT05147558	Phase 2	Pembrolizumab;Lenvatinib
25	A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors	Recruiting	NCT05252416	Phase 1, Phase 2	BLU-222;Carboplatin;Ribociclib;Fulvestrant
26	A Multicenter, Open, Single Arm, Phase II Clinical Study of Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma	Recruiting	NCT05265793	Phase 2	Camrelizumab Combined With Apatinib
27	A Phase II Trial of Nivolumab for Recurrent/Metastatic Carcinosarcoma	Recruiting	NCT05224999	Phase 2	nivolumab
28	MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer	Recruiting	NCT02364713	Phase 2	Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29	A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma	Recruiting	NCT03668340	Phase 2	AZD1775
30	Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -	Recruiting	NCT02203760	Phase 2	Pazopanib plus Gemcitabine;Pazopanib
31	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
32	A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2)	Recruiting	NCT04513665	Phase 2	ZW25
33	A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma	Active, not recruiting	NCT03015129	Phase 2	Durvalumab;Tremelimumab
34	An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma	Active, not recruiting	NCT03694262	Phase 2	Rucaparib;Bevacizumab;Atezolizumab
35	A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)	Active, not recruiting	NCT04106414	Phase 2	Nivolumab;BMS- 986205
36	A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy.	Active, not recruiting	NCT03570437	Phase 2	Paclitaxel;Cediranib;Olaparib
37	An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Active, not recruiting	NCT03648489	Phase 2	Paclitaxel;TAK228
38	A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer	Active, not recruiting	NCT02874430	Phase 2	Metformin Hydrochloride;Doxycycline
39	A Phase Ib/II Single Arm Study of Cabozantinib Plus Dostarlimab in Women With Recurrent Gynecologic Carcinosarcoma	Not yet recruiting	NCT05559879	Phase 1, Phase 2	Cabo + Dostarlimab
40	The EPOCH Study: Phase II Open Labelled Study Investigating the Use of Single Agent Eribulin and Eribulin in Combination With Pembrolizumab in Relapsed Tubo-ovarian or Uterine Carcinosarcoma	Not yet recruiting	NCT05619913	Phase 2	Eribulin Mesylate;Pembrolizumab
41	Randomized Phase 2 Trial of APL-2 With Pembrolizumab vs. APL-2 With Pembrolizumab and Bevacizumab vs. Bevacizumab Alone in Patients With Recurrent Ovarian Cancer and Persistent Malignant Effusion	Not yet recruiting	NCT04919629	Phase 2
42	Pamiparib in Combination With Surufatinib in Patients With Platinum-resistant Ovarian Cancer Who Received Prior Poly (ADP-ribose) Polymerase (PARP) Inhibitors: a Multicenter, Single-arm, Phase Ib/II Trial	Not yet recruiting	NCT05494580	Phase 1, Phase 2	Pamiparib;Surufatinib
43	A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus.	Terminated	NCT00505492	Phase 2	Carboplatin;Cisplatin;Paclitaxel
44	A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer	Terminated	NCT00322881	Phase 2	Paclitaxel;Carboplatin
45	Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus	Terminated	NCT01061606	Phase 2	temsirolimus
46	A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma	Terminated	NCT03509207	Phase 2	Vorinostat Oral Capsule
47	Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-risk Salivary Gland Malignancies	Withdrawn	NCT00984217	Phase 2	Panitumumab
48	A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma	Withdrawn	NCT04149275	Phase 2	Cabozantinib;Ipilimumab;Nivolumab
49	A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion	Withdrawn	NCT03933761	Phase 2	Pamiparib
50	A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma	Unknown status	NCT01454479	Phase 1	Lapatinib and ixempra

Search NIH Clinical Center for Mixed Cell Type Cancer

Cochrane evidence based reviews: mixed tumor, malignant

Sources

Genetic Tests for Mixed Cell Type Cancer

Sources

Anatomical Context for Mixed Cell Type Cancer

Organs/tissues related to Mixed Cell Type Cancer:

MalaCards : Salivary Gland, Uterus, Lymph Node, Ovary, Skin, Breast, Prostate

Sources

Publications for Mixed Cell Type Cancer

Articles related to Mixed Cell Type Cancer:

(show top 50) (show all 1537)

#	Title	Authors	PMID	Year
1	Adenoid Basal Carcinoma with Adenoid Cystic Carcinoma Component of the Uterine Cervix: A Case Report and Literature Review. ⁶²	Kitamura SI...Kato T	36452999	2022
2	Lipomatous mixed tumor of the skin with cystic formation affecting the upper lip: A case report. ⁶²	Nagano R...Kiyoshima T	36168412	2022
3	Mixed tumor of nasal cavity: A case report. ⁶²	Shi JG...Yang Q	36334996	2022
4	Pleomorphic Adenoma of the Palate: A Case Report. ⁶²	Berrerhdoche Z...Elayoubi F	36475232	2022
5	Usefulness of ultrasonography in the preoperative diagnosis of mixed tumor of the skin (chondroid syringoma): A case series with nine patients. ⁶²	Mitsui Y...Asada H	35718945	2022
6	Spatial distribution of CD34 protein in primordial odontogenic tumour, ameloblastic fibroma and the tooth germ. ⁶²	Pereira Prado V...Bologna Molina R	36207782	2022
7	Cutaneous Myoepithelial Neoplasms on Acral Sites Show Distinctive and Reproducible Histopathologic and Immunohistochemical Features. ⁶²	Mehta A...Brenn T	35354162	2022
8	Subungal Mixed Tumor Mimicking Glomus Tumor: A Case Report and Literature Review. ⁶²	Kim J...Kim H	36276218	2022
9	The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review. ⁶²	Wang X...Ma K	36114551	2022
10	Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect. ⁶²	Takahashi K...Sato K	36176626	2022
11	A rare case report of pleomorphic adenoma of the upper lip: An unusual clinical presentation. ⁶²	Prakash C...Devi A	36393934	2022
12	Primary laparoscopic RPLND for pure seminona metastasis: feasibility of supine and lateral approaches. ⁶²	Santos VE...Zequi SC	36037258	2022
13	Tumor cell budding in preoperative biopsies of esophageal and gastroesophageal junction carcinoma independently predicts survival in a grade-dependent manner. ⁶²	Beer A...Schiefer AI	35422326	2022
14	[Ovarian Carcinosarcoma Associated with Cowden Syndrome-A Case Report]. ⁶²	Higuchi D...Otsuka I	35851351	2022
15	Ameloblastic Fibro-Odontoma. ⁶²	Safavi M...Mohammadi F	35748698	2022
16	[Reconstruction of facial skin defects by the V-Y subcutaneous pedicle flap]. ⁶²	Wei MZ...Li X	35725315	2022
17	Gliosarcoma with osteosarcomatous component: A case report and short review illustration. ⁶²	Chen Y...Dong J	35278815	2022
18	Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin. ⁶²	Lindh C...Egevad L	35049068	2022
19	'Teratoid' Hepatoblastoma: An Intriguing Variant of Mixed Epithelial-Mesenchymal Hepatoblastoma. ⁶²	Sergi CM...Dicken B	35455609	2022
20	Proliferation in pleomorphic adenoma: Lights and shadow on this parameter, in a neoplasm showing unpredictable behavior-An immunohistochemical study and review of the literature. ⁶²	De Rosa F...Guadagno E	35094844	2022
21	Evolution of superficial spreading melanoma to resemble desmoplastic melanoma: case report. ⁶²	Cook MG...Green AC	34286349	2022
22	Uterine Adenosarcoma in a Teen Ager. ⁶²	Wang Y...Yuan Y	35633000	2022
23	Brenner tumors of the ovary: clinical features and outcomes in a single-center cohort ⁶²	Yuksel D...Koc S	35000896	2022
24	Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor. ⁶²	Tamura S...Konishi I	35448164	2022
25	High grade uterine adenosarcoma with sarcomatous overgrowth in a young woman amenable to primary surgical reduction: A case study and literature review. ⁶²	Dowding DD...Guirguis AS	35036509	2022
26	Odontogenic carcinosarcoma - A rare case report with review of literature. ⁶²	Majumdar S...Alekhya B	35450233	2022
27	Predicting cancer immunotherapy response from gut microbiomes using machine learning models. ⁶²	Liang H...Kong HH	35875611	2022
28	The Histopathological Types and Distribution Characteristics of Gastric Mixed Tumors. ⁶²	Zhu FH...Wang SN	35785186	2022
29	Acquired chemoresistance drives spatial heterogeneity, chemoprotection and collective migration in pancreatic tumor spheroids. ⁶²	Thege FI...Kirby BJ	35617275	2022
30	Combination of Adenomyoepithelioma and Adenoid Cystic Carcinoma of the Breast: A Case Report of an Uncommon Histopathological Entity. ⁶²	Spyrou A...Noussios G	35064096	2022
31	Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors. ⁶²	Macagno N...Battistella M	35158743	2022
32	[Endometrioide-type cervical adenomyoma]. ⁶²	Asencio Aguedo AY...Cerrillo Alvarez GG	34980438	2022
33	Clinical, Radiological and Histopathological Features of Patients With Lacrimal Gland Enlargement. ⁶²	Jamshidian Tehrani M...Mokhtari M	35014239	2021
34	Histology transformation-mediated pathological atypism in small-cell lung cancer within the presence of chemotherapy: A case report. ⁶²	Ju Q...Zhang J	35004997	2021
35	Rare Case Report: Young Male Hard Palate Pleomorphic Adenoma. ⁶²	Gupta P...Gupta M	34692463	2021
36	A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. ⁶²	Brendlin AS...Othman AE	34795006	2021
37	Cutaneous adenomyoepithelioma with histopathological heterogeneity: A case report. ⁶²	Shiomi T...Moriya T	34473865	2021
38	Early and late recurrences in lymph node-negative gastric cancer: a retrospective cohort study. ⁶²	Sun JW...Hou XH	34873937	2021
39	Apocrine mixed tumor with pilomatrical differentiation. ⁶²	He L...Vandergriff T	34291474	2021
40	Carcinoma Expleomorphic Adenoma of the Lacrimal Gland. ⁶²	Vahdani K...Rose GE	33710040	2021
41	Survival and prognostic factors of salivary gland malignant mixed tumor-not otherwise specified: A population-based analysis. ⁶²	Soffer JM...O'Leary MA	34171696	2021
42	Malignant mixed tumor of the skin on the anterior chest. ⁶²	Nakashima H...Fukushima S	34240174	2021
43	Carcinoma with Triphasic Differentiation Arising from Inverted Papilloma in Sinonasal Sinus: A Rare Case with Molecular Characterization. ⁶²	Kim SW...Na K	34679524	2021
44	Cytodiagnosis of chondroid syringoma-Series of three cases. ⁶²	Agarwal R...Agarwal D	34174020	2021
45	Mixed Intraepithelial Neoplasia-Well-Differentiated Neuroendocrine Tumor of the Gallbladder: A Hitherto Unreported Combination. ⁶²	Kovari B...Jiang K	33423570	2021
46	Editorial Comment to A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes. ⁶²	Sekito T...Sadahira T	34497988	2021
47	A case of mixed tumor formed by metastasis of urothelial carcinoma and malignant lymphoma to the same lymph nodes. ⁶²	Kobayashi S...Inoue K	34497987	2021
48	Effectiveness of Preoperative Embolization in Patients with Spinal Metastases: A Systematic Review and Meta-Analysis. ⁶²	Gao ZY...Xia Q	34153484	2021
49	Exenteration and Adjuvant Radiotherapy for Primary Carcinosarcoma of the Anterior Orbit: A Case Report. ⁶²	Fernandez C...Shi W	33481539	2021
50	An atypical chondroid syringoma with malignant degeneration: Utility of comparative genomic hybridization in confirming the diagnosis. ⁶²	Zia S...Friedman BJ	33470448	2021

Sources

Genes for Mixed Cell Type Cancer

Genes related to Mixed Cell Type Cancer (0 elite genes):

(show all 35)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR542	MicroRNA 542	RNA Gene	8.82	DISEASES inferred ¹⁴ ¹⁴
2	H2AC18	H2A Clustered Histone 18	Protein Coding	8.43	DISEASES inferred ¹⁴ ¹⁴
3	SERPINA3	Serpin Family A Member 3	Protein Coding	7.84	DISEASES inferred ¹⁴ ¹⁴
4	TP53	Tumor Protein P53	Protein Coding	7.62	DISEASES inferred ¹⁴
5	KRT7	Keratin 7	Protein Coding	7.14	DISEASES inferred ¹⁴
6	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	6.99	DISEASES inferred ¹⁴
7	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	6.98	DISEASES inferred ¹⁴
8	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.97	DISEASES inferred ¹⁴
9	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.97	DISEASES inferred ¹⁴
10	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.94	DISEASES inferred ¹⁴
11	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.94	DISEASES inferred ¹⁴
12	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.93	DISEASES inferred ¹⁴
13	SYP	Synaptophysin	Protein Coding	6.89	DISEASES inferred ¹⁴
14	MME	Membrane Metalloendopeptidase	Protein Coding	6.83	DISEASES inferred ¹⁴
15	PGR	Progesterone Receptor	Protein Coding	6.77	DISEASES inferred ¹⁴
16	ESR1	Estrogen Receptor 1	Protein Coding	6.71	DISEASES inferred ¹⁴
17	KRT5	Keratin 5	Protein Coding	6.65	DISEASES inferred ¹⁴
18	PAX8	Paired Box 8	Protein Coding	6.62	DISEASES inferred ¹⁴
19	PPP2R1A	Protein Phosphatase 2 Scaffold Subunit Aalpha	Protein Coding	6.62	DISEASES inferred ¹⁴
20	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.6	DISEASES inferred ¹⁴
21	CTNNB1	Catenin Beta 1	Protein Coding	6.57	DISEASES inferred ¹⁴
22	CALD1	Caldesmon 1	Protein Coding	6.54	DISEASES inferred ¹⁴
23	CALB2	Calbindin 2	Protein Coding	6.49	DISEASES inferred ¹⁴
24	WT1	WT1 Transcription Factor	Protein Coding	6.44	DISEASES inferred ¹⁴
25	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	6.43	DISEASES inferred ¹⁴
26	AFP	Alpha Fetoprotein	Protein Coding	6.43	DISEASES inferred ¹⁴
27	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.43	DISEASES inferred ¹⁴
28	CDH1	Cadherin 1	Protein Coding	6.42	DISEASES inferred ¹⁴
29	MYOG	Myogenin	Protein Coding	6.41	DISEASES inferred ¹⁴
30	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	6.4	DISEASES inferred ¹⁴
31	ENO2	Enolase 2	Protein Coding	6.39	DISEASES inferred ¹⁴
32	CHGA	Chromogranin A	Protein Coding	6.38	DISEASES inferred ¹⁴
33	PLAG1	PLAG1 Zinc Finger	Protein Coding	6.32	DISEASES inferred ¹⁴
34	MLH1	MutL Homolog 1	Protein Coding	6.31	DISEASES inferred ¹⁴
35	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.3	DISEASES inferred ¹⁴

Sources

Variations for Mixed Cell Type Cancer

Sources

Expression for Mixed Cell Type Cancer

Search GEO for disease gene expression data for Mixed Cell Type Cancer.

Sources

Pathways for Mixed Cell Type Cancer

Pathways related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 64)

#	Super pathways	Score	Top Affiliating Genes
1	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.81	TP53 PTEN PPP2R1A PIK3CA KRAS KIT
2	Signal Transduction ⁶⁶	13.71	TP53 PTEN PPP2R1A PIK3CA PGR KRAS
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.42	TP53 PTEN PPP2R1A KRAS KIT HRAS
4	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.36	ERBB2 ESR1 HRAS KIT KRAS PIK3CA
5	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.04	TP53 PTEN PPP2R1A PIK3CA KIT ESR1
6	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13	PIK3CA PGR KRAS HRAS H2AC18 ESR1
7	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.89	TP53 PTEN PPP2R1A PIK3CA KRAS KIT
8	Malignant pleural mesothelioma ⁷⁴	12.71	TP53 PTEN PIK3CA KIT HRAS
9	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.69	ERBB2 ESR1 HRAS KIT KRAS PGR
10	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.65	PTEN PPP2R1A PIK3CA KIT ESR1 ERBB2
11	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.63	TP53 PPP2R1A PIK3CA KRAS KIT HRAS
12	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.6	TP53 PIK3CA KRAS HRAS ERBB2
13	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.6	TP53 PTEN PIK3CA KRAS KIT HRAS
14	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.48	ERBB2 HRAS KRAS PIK3CA TP53
15	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.43	TP53 PIK3CA KRAS HRAS ERBB2
16	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.42	PIK3CA KRAS HRAS ESR1
17	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.42	PIK3CA KRAS HRAS ESR1
18	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.41	PIK3CA KRAS KIT HRAS ERBB2
19	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.4	TP53 PTEN PIK3CA HRAS ESR1 ERBB2
20	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.34	ERBB2 ESR1 HRAS PIK3CA
21	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.33	PTEN PIK3CA KRAS HRAS
22	Focal adhesion ⁷⁴	12.3	PTEN PIK3CA HRAS ERBB2
23	Signaling by FGFR2 ⁶⁶ Show member pathways FGFR2 ligand binding and activation ⁶⁶ FGFR2b ligand binding and activation ⁶⁶ Signaling by FGFR ⁶⁶	12.28	PPP2R1A PIK3CA KRAS HRAS
24	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.27	TP53 PTEN PIK3CA HRAS
25	Ras signaling ⁷⁴	12.26	HRAS KIT KRAS PIK3CA
26	Signaling by ERBB2 KD Mutants ⁶⁶ Show member pathways Constitutive Signaling by Overexpressed ERBB2 ⁶⁶ GRB2 events in ERBB2 signaling ⁶⁶ PI3K events in ERBB2 signaling ⁶⁶ PI3K events in ERBB4 signaling ⁶⁶ PLCG1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB2 signaling ⁶⁶ SHC1 events in ERBB4 signaling ⁶⁶ Signaling by ERBB2 ECD mutants ⁶⁶ Signaling by ERBB2 in Cancer ⁶⁶ Signaling by ERBB2 TMD/JMD mutants ⁶⁶	12.25	PIK3CA KRAS HRAS ERBB2
27	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.19	TP53 PIK3CA KRAS HRAS
28	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.17	TP53 PTEN PIK3CA KRAS HRAS ERBB2
29	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.16	TP53 PTEN PIK3CA HRAS
30	Integrated breast cancer pathway ⁷⁴	12.16	TP53 PTEN KRAS ESR1
31	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.14	ERBB2 HRAS PIK3CA PTEN
32	mTOR Signaling ⁶⁵	12.1	TP53 PTEN KRAS ERBB2
33	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.04	PIK3CA KRAS HRAS ERBB2
34	Development EPO-induced Jak-STAT pathway ²² Show member pathways EPO receptor signaling ⁷⁴ Signaling events mediated by Stem cell factor receptor (c-Kit) ⁶¹	12	PTEN PIK3CA KIT HRAS
35	Gastrin signaling pathway ⁷⁴	11.98	PIK3CA KRAS KIT HRAS
36	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	11.92	PIK3CA PGR KRAS HRAS ESR1 ERBB2
37	Signaling by SCF-KIT ⁶⁶ Show member pathways Regulation of KIT signaling ⁶⁶ Signaling by KIT in disease ⁶⁶ Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants ⁶⁶	11.91	PIK3CA KRAS KIT HRAS
38	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.9	PTEN PIK3CA KRAS HRAS ERBB2
39	Signaling by PDGF ⁶⁶ Show member pathways Downstream signal transduction ⁶⁶	11.85	PIK3CA KRAS HRAS
40	Thyroid hormones production and peripheral downstream signaling effects ⁷⁴	11.83	TP53 PIK3CA HRAS
41	DAP12 interactions ⁶⁶ Show member pathways DAP12 signaling ⁶⁶	11.78	PIK3CA KRAS HRAS
42	VEGF Pathway (Tocris) ⁷⁰ Show member pathways Sorafenib Pharmacodynamics ⁶⁰	11.78	PIK3CA KRAS KIT HRAS
43	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.77	TP53 PIK3CA KRAS HRAS
44	AP-1 transcription factor network ⁶¹	11.74	TP53 PTEN ESR1
45	DNA damage response (only ATM dependent) ⁷⁴	11.74	TP53 PTEN PIK3CA KRAS HRAS ERBB2
46	16p11.2 proximal deletion syndrome ⁷⁴	11.72	TP53 PTEN PPP2R1A ESR1
47	BCR signaling pathway ⁶¹	11.71	PTEN PIK3CA HRAS
48	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	11.71	TP53 PTEN PIK3CA PGR KRAS KIT
49	Serotonin HTR1 group and FOS pathway ⁷⁴ Show member pathways Serotonin receptor 2 and ELK-SRF/GATA4 signaling ⁷⁴ Serotonin receptor 4/6/7 and NR3C signaling ⁷⁴	11.68	PIK3CA KRAS HRAS
50	BDNF-TrkB signaling ⁷⁴ Show member pathways Synaptic signaling pathways associated with autism spectrum disorder ⁷⁴	11.67	PTEN KRAS HRAS

Sources

GO Terms for Mixed Cell Type Cancer

Biological processes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	fibroblast proliferation	GO:0048144	9.63	TP53 HRAS ESR1
2	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.56	TP53 ESR1
3	regulation of long-term neuronal synaptic plasticity	GO:0048169	9.43	SYP KRAS HRAS
4	positive regulation of phospholipase C activity	GO:0010863	9.1	KIT HRAS ESR1